HLB Pep Co., Ltd. (196300.KQ)
KOSDAQ · KRW · Basic Materials · Chemicals
₩4,075 (-1.69%) as of
Key statistics
- Market cap
- 38.21B
- Dividend yield
- 0.00%
- 52-week range
- 3,510.00 – 9,530.00
- Beta
- 0.17
- Revenue (TTM)
- 5.54B
- Profit margin
- -57.53%
- Volume
- 1.64k
About HLB Pep Co., Ltd.
HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes; AGM-217 indicated for the treatment of Type 2 diabetes and obesity; and AGM-260 indicated for the treatment of Ulcerative colitis. The company was formerly known as Anygen Co., Ltd. and changed its name to HLB Pep Co., Ltd. in April 2025. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.
- Sector
- Basic Materials
- Industry
- Chemicals
- Headquarters
- Gwangju-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.